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Medication therapy management 
services (MTMS) have been shown to 
improve patient health outcomes through 
improved control of chronic disease and more 
careful attention to potential drug-drug 
interaction, Insurers have found MTMS to be 
quite effective at both cost and patient risk 
reduction, Both patients and pharmacists 
have a generally positive outlook on the 
MTM process; however, many pharmacists 
muggle to balance their current clinical 
responsibilities with the added workload of 
MTMS, This study was conducted to identifY 
the barriers to MTMS provision encountered 
by Indiana pharmacists, 
LITERATURE REVIEW 
MTMS became a required service as 
part of the Medicare Modernization Act of 
2003 (MMA) , This piece of legislation 
requires all Medicare Part D prescription 
drug plan sponsors (PDPS) to create a 
medication therapy management program 
for targeted patients in order to improve 
overall knowledge of medication usage 
(American Society of Health System 
Pharmacists, 2006), According to Medicare, 
individuals who are "targeted" to receive 
MTMS are those who have multiple chronic 
rliseases (such as diabetes, asthma, 
hypertension, etc,), have been prescribed 
several covered Part D medications, and are 
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paying at least $4,000 in out-of-pocket 
expenses for their medication each year 
(American Society of Health Systems 
Pharmacists, 2006), 
Insurance companies are eager to 
implement programs to assist patients in 
managing their medications because it is a 
relatively small investment which has been 
demonstrated to save a significant amount of 
money, For example, Hahn and Shapiro 
(2007) point out the cost differential between 
patients with well-controlled diabetes versus 
diabetes patients whose condition is not under 
control. Even though the former patient 
might require the insurer to pay more for 
additional prescription drugs to keep the 
diabetes controlled, the total treatment cost 
for the controlled patient is between $8,000 
and $13,000 lower per year than the 
uncontrolled patient, These savings, largely a 
result of MTM intervention by pharmacists, 
are primarily due to the reduction of 
potentially expensive complications for those 
with uncontrolled diabetes, Insurance plans 
have the freedom to establish fees involved in 
providing MTMS, According to the Center 
for Medicaid and Medicare Services (2006), 
Medicare has mandated that potential Part D 
sponsors provide explanation as to how 
expended resources and time have been 
factored into the reimbursement amount 
requested by MTM providers, 
Touchette, Burns, Bough, & Blackburn 
(2006) suggest that one potential 
problematic area involves the eligibility 
restrictions for MTM services, They state: 
"although an economic incentive may be 
perceived in some cases", the fiscal impact 
of.. ,an MTM program may depend less on 
the condition being treated and more on the 
potential of the involved medications to 
result in benefit or cause harm" (p, 688), 
Thus, to truly be effective, insurance 
programs may need to restructure their 
eligibility requirements to include more 
chronic conditions based upon medication 
risks, rather than limiting patients' eligibility 
simply in terms of how "costly" their specific 
condition may become, 
Similarly, Cameron (2005) touches 
on this same topic of patient "targeting," 
suggesting that some MTMS may lead to 
improved patient compliance with drug 
therapy, thereby creating less profitability 
for the insurance companies because of 
increased prescription expenses, To help 
combat this potential problem of 
insurance companies becoming too 
exclusive with patient selection for 
MTMS, Cameron suggests that physicians 
and other healthcare professionals be 
authorized to refer high-risk patients who 
may not meet the established criteria to 
receive MTM interventions, 
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Regarding effectiveness, Touchette et al. 
(2006) also mention that programs offering 
a comprehensive list of services may be able 
to better identify problem areas and 
subsequently find solutions to those issues 
via contact with the patient's physician 
and/or multiple MTM progress visits. The 
Center for Medicare and Medicaid Services 
(2006) notes that insurance plans initially 
will have the opportunity to choose the 
design of their programs using any means of 
communication, although they do suggest 
that future regulations may be implemented 
if particular methods of performing MTMS 
prove more effective than others. 
There is no doubt that patients are 
taking advantage of MTM opportunities. 
While some patients have low expectations 
regarding pharmacy services and only wish 
to be assured that they have the correct 
medication (Summary, 2005), many seem 
ready and willing to take advantage of these 
consultation sessions with trusted medical 
professionals (Lipowski, 2007; Swidan, 
Mitzrzyk, & Samuels, 2007). 
Pharmacists also believe that MTM 
programs are beneficial, as they move 
pharmacies in the direction of giving 
practitioners official documentation of their 
consultation time. Breeman (2007) noted 
that "Managed care pharmacists want a 
closer, more personal relationship with their 
patients and to do what they truly love to 
do" (p. 52). Pharmacist Ernest Dole, 
explaining the need for a formal recognition 
of services, notes that" ... most pharmacists 
do not typically bill for the patient care 
services they provide. And without 
substantial development of that ability, the 
profession's survival may be threatened" 
(Sipkoff, 2007, para. 4). Furthermore, 
MTM interventions may take longer than 
expected, but the results are promising: "I 
think it's rewarding for the 
patients ... They're happy, and they know 
there is somebody they can go to" (Gowda 
& Provost, 2005, p. 1646). 
Pharmacists with MTMS experience 
affirm that the services increase patient 
compliance and confidence because 
medications are being administered 
correctly. However, they also note that 
MTMS also present conflicts of interest in 
terms of funding and coordinating care 
with other professionals (Gowda & 
Provost, 2005). The bottom line is that "the 
value of pharmacists as providers of patient 
care services such as MTM is 
underappreciated" (Swidan, Mitrzyk, & 
Samuels, 2007, p. 677). The authors, all 
pharmacists themselves, recognize MTM as 
a valuable program but insist that 
pharmacists must "take immediate, decisive 
steps toward demonstrating their value to 
employers, insurance companies, and 
government officials" (p. 677). Paul (2007) 
underscores the importance of recognition, 
noting that pharmacies must fairly 
compensate for the additional time and 
effort put forth by pharmacists. 
Recent research has shown that 
pharmacists are eager to implement 
MTMS, but are counting on Medicare Part 
D Prescription Drug Plans (PDPs) to assist 
in both implementation and 
reimbursement logistics (Boyd, Boyd, & 
Zillich, 2006). Of particular concern is lack 
of commitment to face-to-face meetings -
one study reported that telephone centers 
and mail campaigns comprised more than 
half of the PDP provisions (Boyd, Boyd, & 
Zillich, 2006). For many pharmacists, the 
motivation is present, but more precise 
definitions and guidelines regarding their 
MTMS are needed. 
The purposes and benefits of 
medication therapy management (MTM) 
have been well documented. Assuming 
proper implementation, MTMS present 
myriad benefits for pharmacists, patients, 
physicians, and the pharmacy profession as a 
whole. MTMS function to ('ensure 
appropriate use of [Medicare] Part D drugs 
to optimize therapeutic outcomes through 
improved medication use and to reduce the 
risk of adverse events including drug-drug 
interactions" (Altman, 2007). Additionally, 
MTMS are designed to "improve care, 
enhance communication among patients 
and providers, improve collaboration 
among providers, and optimize medication 
use for improved patient outcomes" 
(APhA/NACDS Foundation, 2005). 
Scholars have recently begun to 
empirically demonstrate the benefits of 
MTM in terms of improved patient 
outcomes. Bunting and Cranor (2006) 
tracked clinical, economic, and humanistic 
outcomes of a recently implemented MTM 
program for asthma patients over a five-year 
period. They discovered that 70 percent of 
patients had improved breathing rates 
following the program. As far as economic 
savings, an average of $1,230/patient/year 
savings in indirect costs in terms of 
workplace absenteeism (physically missing 
work) and presenteeism (being at work but 
unable to perform due to health condition) 
were found. For humanistic outcomes, the 
categories of shortness of breath, tightness of 
chest, chest pains, and coughing/wheezing 
all showed significant improvement upon 
follow-up visits. 
The pharmaceutical industry as 
a whole stands to gain from the 
implementation and execution of MTMS. 
Pharmacy professionals have had a hard 
time shedding their "behind-the-counter 
persona," (Bari & Davis, 2007, p. 2), and 
MTMS provide for more one-on-one 
contact with customers, thereby reducing 
the physical and psychological distance 
between pharmacists and patients, 
ultimately resulting in the degree of open 
communication needed for effective drng 
therapy. Pharmacies, because they are the 
most visited health-care setting, are the most 
appropriate place for MTMS to be rendered; 
hence, pharmacists are in the best position to 
administer the one-on-one communication 
that MTMS warrant (Cranor, Bunting, & 
Christiansen, 2003). 
MTM is an opportunity for 
pharmacists to demonstrate their in-depth 
knowledge of the nuances of drug therapy. 
Most physicians simply do not have the 
time, and allied health care professionals 
(i.e., Nurse Practitioners and Physician 
Assistants) lack the clinical background 
required for such interventions (Gebhart, 
2004). Pharmacists have the responsibility 
(and opportunity) to "step outside their 
pharmacy box, educate the public and the 
medical profession, and market their 
services" (Schuh, 2008, p. 1). 
With all of the benefits and opportunities 
of MTMS, they are not without their 
criticisms and drawbacks. Often, the sheer 
volume of work required of pharmacists may 
eliminate any extra time for these types of 
services (Altman, 2007). These situations may 
lead to the outsourcing of MTMS to other 
pharmacists outside of the immediate 
pharmacy setting. This scenario seems to run 
contrary to the hope that MTMS would 
bridge the gap between pharmacists and 
patients in terms of expanding 
communication and developing relationships. 
Some of the tremendous opportunities 
MTMS present can also be viewed as extra 
pressure on pharmacists. Indeed, pharmacists 
assume great responsibility that scholars 
recognize: "the onus of popularizing the 
development of quality MTMS now falls 
squarely on the shoulders of the pharmacist" 
(Bari & Davis, 2007, p. 8) . 
Furthermore, skeptics fear that MTMS 
may not be a revenue-generating activity and 
will ultimately create a divide between 
pharmacists administering the MTMS and 
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the prescrIptIOn drug plan sponsors who 
design and manage the benefits (Cantwell, 
2005). A lack of standardization of what 
MTMS entail is also a salient concern. This 
includes an unclear definition of what 
should be included in MTMS, a lack of 
understanding about the process of 
reimbursement, and unclear expectations 
about which patients should receive the 
services. 
A number of studies have been 
conducted to identifY possible barriers to the 
provision of MTM services based on the 
observation that many pharmacists express 
positive feelings about MTMS but largely 
fail to provide these interventions. Several 
factors have been identified that may explain 
this inconsistency. One study found that 
many pharmacists reported lack of 
confidence regarding their ability to 
successfully complete the patient care 
involved in MTMS (Odedina, Segal, 
Hepler, Lipowski, & Kimberlin, 1996). 
Another study identified the physical layout 
of stores and space allocated for pharmacy-
related services to be a potential barrier to 
MTMS provision. Pharmacists without 
access to private consultation rooms may 
avoid MTMS and other patient interaction 
due to privacy concerns (Raisch, 1993). This 
barrier has become even more of an issue as 
new HIPAA guidelines enforce the 
confidentiality of patient health 
information. This study also identified 
numerous barriers related to dealing with 
prescribing physicians. Perceived barriers 
included difficulty making contact due to 
physician/pharmacist mutual availability 
and negative physician attitudes toward 
pharmacists' recommendations. Whether 
these barriers are real or only perceived, they 
serve to effectively reduce the amount of 
pharmaceutical services provided in the 
pharmacy. 
A number of studies have recognized 
insufficient reimbursement as a barrier. In a 
comprehensive study of payment structures 
for MTM sessions, the Lewin Group found 
$1.00 to $2.00 per minute to be an adequate 
figure to cover pharmacist labor costs 
involved in providing MTMS. Total costs, 
according to industry estimates, are higher, 
at $2.00 to $3.00 per minute (Lewin Group, 
2005). The amounts that state Medicaid 
programs pay for MTMS vary. For example, 
Iowa Medicaid pays $75.00 for an initial 
assessment, $40.00 for a new problem or 
follow-up assessment, and $25.00 for any 
preventative follow-up assessments. In 
contrast, Mississippi and Wisconsin 
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Medicaid pay $20.00 and $40.11 per visit, 
respectively. In many cases, these 
reimbursement amounts do not cover the 
costs of pharmacists who are providing the 
services, and thus create a real barrier to the 
implementation and execution of successful 
programs. 
Another study found that some 
pharmacists employed by chain pharmacies 
believed they should receive some of the 
reimbursement that their stores receive for 
their interventions (Rochester & Currey, 
1999). Pharmacists who hold this opinion 
are less likely to conduct MTM 
interventions if they believe it creates 
additional work with little individual 
benefit. 
METHOD 
Mter reviewing published studies and 
general descriptions about pharmacy 
practices and patient care services, a 24-item 
scale was developed to measure pharmacist 
attitudes and practices surrounding MTMS 
as well as to assess the presence and severity 
of various predicted barriers. In addition to 
these Likert-scale questions, a pool of 
demographic and pharmacy characteristic 
questions were included to assess other 
characteristics which might be related to 
MTMS provision. Finally, several open-
ended questions were developed to solicit 
unstructured feedback about pharmacists' 
perceptions of MTMS. This questionnaire 
was distributed to Indiana pharmacists via 
the Indiana Pharmacist Alliance 
Community Pharmacy Academy e-mail list. 
A total of 81 responses were collected from 
practicing pharmacists in the state of 
Indiana. Mter evaluating these responses, six 
in-depth interviews were conducted to 
further probe the nature of MTMS barriers. 
From the survey responses and in-depth 
interviews, nine barriers to MTMS 
implementation in the state of Indiana 
emerged. 
RESULTS 
Barl'iel' #1: 
Lack of Management SUPP0l't 
Research suggests that though MTMS 
present tremendous opportunities for both 
pharmacists and patients, they can also put 
extra pressure on pharmacists. When lack of 
time, training, structural resources, and 
sufficient reimbursement are compounded 
by little or no support from management, 
the motivation and ability to provide 
MTMS suffer. MTMS in all pharmacy 
settings "should include structures 
supporting the establishment and 
maintenance of the pharmacist-patient 
relationship" (MTM in pharmacy practice, 
2008), and management is at the core of 
these structures. Lack of management 
support is more of a roadblock than a barrier 
- regardless of pharmacists' attitudes toward 
MTMS, the feasibility of successful 
implementation and maintenance rests on 
continued management support. This claim 
was supported by our survey: 100 percent of 
pharmacists reporting lack of management 
support for MTMS also reported that their 
pharmacy did not provide MTMS. 
Ba1'1'iel' #2: 
Lack of Tmining 
Based upon the literature review, we 
expected to see lack of training as a barrier 
for pharmacists' provision of MTMS. One 
salient concern about MTMS was lack of 
standardization. Many pharmacists believe 
there is an ambiguous definition about what 
comprises an MTM, exhibit a lack of 
understanding about the process of 
reimbursement, and possess unclear 
expectations about who should receive 
services. In short, because there is little 
standardization of MTMS, pharmacists 
lack the initial knowledge and clinical 
practice to successfully perform requested 
interventions. 
From the survey, approximately 30 
percent of our respondents reported having 
no training in providing MTM services. 
Similarly, 33 percent of respondents 
reported that they were not well prepared in 
school to conduct MTM services. These 
responses demonstrate, in part, the training 
gap pharmacists experience when beginning 
to provide MTMS. If pharmacists are not 
adequately informed, educated, and trained 
in MTM provision, MTMS are not 
rendered and patient care suffers. Several 
interviewees noted that the "training" they 
had received was informal, and oftentimes 
"on-the-job." One interviewee stated: 
"Much of my training has been practical, 
and hands on, from experience, not so much 
classroom training." A great number of 
responses to the open-ended survey 
questions demonstrate the significant role 
training plays in the provision of MTMS. 
Barl'iel' #3: 
Inadequate Patient 
Education and Awareness 
While research has shown that patients 
generally have a positive attitude toward 
MTMS and that many are indeed taking 
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advantages of these services, our survey and 
interviews indicate room for improvement 
in patient education. As expected, MTMS 
are believed to improve the quality of 
customer care, and only 17 percent of 
pharmacists surveyed felt their patients were 
not open to MTMS. However, these results 
do not necessarily indicate that patients are 
not experiencing difficulty in understanding 
the process or benefits of MTMS. 
Barrier #4: 
Lack of Time 
Based on the literature review, lack of 
time was expected to be a barrier to 
provision of MTMS. Pharmacists have 
consistently expressed feeling the pressure 
of time constraints and the added 
responsibility of MTM provision only adds 
to the stress. 
Our survey revealed that 59 percent of 
respondents felt they lacked the time to 
provide requested MTMS. An additional 
14 percent remained neutral on the issue 
of time. Approximately 30 percent of 
the responses to the open-ended survey 
question regarding why MTMS were 
not currently being provided included 
comments referencing time as a barrier. 
Barrier #5: 
Lack of Private Space 
Concerns about patient confidentiality 
in light of HIPAA requirements are salient 
concerns for many pharmacists. The 
physical layout of stores and space allocated 
for pharmacy-related activity was found 
by one study to be a perceived barrier 
by pharmacists due to a lack of privacy. 
Furthermore, current layouts of most 
pharmacies are not conducive to the 
comfortable climate necessary for open 
dialogue in which the patient can feel free to 
ask questions. Pharmacists without access to 
private consultation rooms may avoid 
MTMS and other patient interaction due to 
privacy concerns (Raisch, 1993). 
Our survey supported the published 
literature related to this barrier. Of our 
respondents, 45 percent reported lack of 
private space for consultation was a barrier 
to providing MTM services. 
Barrier #6: 
Complexity of Required 
Documentation 
A common mantra in many fields of 
health care is "if you didn't document it, 
you didn't do it." Pharmacists have 
experience maintaining prescription records, 
but many lack experience documenting 
patient care activities. More comprehensive 
documentation practices are essential when 
pharmacists implement patient care services, 
including MTM. Based on our literature 
review and primary research, the complexity 
of required MTMS documentation for the 
service and for reimbursement has been 
identified as a barrier. 
Of survey respondents, 41 percent 
reported that the documentation 
requirements for MTMS services are a 
burden. Similarly indicating a problem with 
the required documentation, 39 percent of 
respondents indicated that they often 
provide requested MTMS services without 
completing the documentation required for 
reimbursement. 
In the survey, pharmacists expressed 
that "documentation needs to be automated, 
perhaps scan a bar code to identify the 
medication/patient, and then use a touch 
screen to verify the proper information was 
covered." Respondents wished there was 
"easier paperwork to complete, more time to 
take care of monthly patient[s]." 
Barrier #7: 
Difficulty Interacting 
With Physicians 
The results of our study were consistent 
with the investigations conducted by Raisch 
(1993) in terms of difficulty interacting with 
primary care physicians. Similar to Riasch's 
findings, pharmacists in Indiana reported 
difficulty making contact with prescribing 
physicians due to schedule availabilities, and 
many reported that physicians often have a 
negative view of pharmacists as part of a 
patient's overall healthcare team. 
From the survey, nearly 37 percent of 
respondents reported experiencing difficulty 
interacting with customers' primary care 
physicians. Nearly 23 percent of respondents 
were unsure when asked about difficulty 
interacting with physicians, which may 
indicate that some physicians and practices 
are easier to contact and collaborate with 
than others. A number of comments from 
the open-ended questions provided more 
insight into the day-to-day difficulties 
pharmacists may encounter when dealing 
with primary care physicians. 
Based on these comments and 
additional information received from 
the interview, two primary areas of 
concern were identified: communication 
and collegiality. Pharmacists often have 
difficulty communicating with primary care 
physicians. Many respondents reported long 
delays in being able to speak to physician, or 
problems with messages being incorrectly 
relayed or ignored by nursing staff. This 
difficulty in connecting with physicians 
ultimately reduces pharmacists' willingness 
to conduct MTM and other clinical 
pharmacy services that require coordination 
with other health professional. 
In terms of collegiality, many 
pharmacists reported being treated as 
"second class citizens" in the healthcare 
industry. Rather than being treated as an 
integral part of a healthcare system, 
pharmacists' efforts are often rebuffed by 
physicians. One respondent reported being 
told by a physician: "You don't need to do it 
(MTM) for my patients - they know all they 
need to do." Part of this lack of collegiality 
may be due to physicians feeling threatened 
by pharmacists' therapy suggestions. One 
pharmacist remarked "It's kind of a 'turf' 
thing: when I start making suggestions, they 
[physicians] might feel like you're stepping 
on toes." 
Barrier #8: 
Lack of Access to InfOl'mation 
Overall, access to information in the 
provision of MTMS has been given little 
attention in the pharmacy literature. 
However, Raisch (1993) found that 
pharmacists cite "inadequate patient 
information" as a barrier to providing 
MTMS. Another common concern reported 
is lack of consistent and comprehensive 
patient information, especially from patients 
who trade at multiple pharmacies and see 
multiple physicians. Despite attempts in the 
literature to identify possible barriers early 
on, lack of information remains an under-
researched, unforeseen problem. 
Results from our survey revealed that 
60 percent of pharmacists do not believe 
they have access to the necessary 
information to provide MTMS. Based on 
this result and the recommendations from 
our interview respondents, it is clear that 
increasing the amount of information 
available to pharmacists will increase 
pharmacists' levels of comfort with 
recommending drug therapy modifications. 
Without access to the same information, 
physicians and pharmacists are unable to 
provide consistent, quality care. 
Barrier #9: 
Inadequate Reimbul'sement 
Based on the literature review, this 
barrier was expected, and it did prove to be 
a significant barrier for the surveyed 
Second Quarter 2008 
,)harmacists, Many pharmacists expressed 
~pinions consistent with Rochester & 
Currey's 1999 observation that pharmacists 
are unlikely to conduct MTM interventions 
if they believe it creates additional work with 
little individual benefit, 
From the survey, 14 percent of 
pharmacists indicated that they did not 
provide MTMS because compensation was 
not adequate, A further 45 percent 
remained unsure of their answer to this 
question, This may indicate, at least 
partially, a segment of the population that 
does conduct MTMS but feels the 
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